ALLR
Allarity Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.42
−0.70%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +54.3%
- EBIT
- +59.7%
- EPS
- +91.5%
- Free cash flow
- +19.5%
- Operating cash flow
- +18.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -26.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- +54.4%
- EBIT
- +53.7%
- Net income
- +54.2%
- EPS
- +95.1%
- Free cash flow
- +16.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026